银屑病亚临床肝病与亚临床动脉粥样硬化相关:两项观察性研究结果
该研究基于欧洲队列(76例银屑病患者与76例对照)和美国队列(162例银屑病患者),探讨银屑病中亚临床肝病对亚临床动脉粥样硬化的影响。欧洲队列显示银屑病患者非酒精性脂肪性肝病患病率高于对照,合并脂肪肝的银屑病患者亚临床动脉粥样硬化患病率更高,且超声肝肾指数是亚临床动脉粥样硬化的决定因素之一;美国队列显示肝脏FDG摄取高者冠状动脉非钙化、纤维脂肪及脂质丰富坏死核心负荷更高。结果提示银屑病亚临床肝病与亚临床动脉粥样硬化相关,反映其下游心血管效应。
要点
- 银屑病合并脂肪肝者亚临床动脉粥样硬化患病率更高,应关注心血管风险。
- 超声肝肾指数与银屑病亚临床动脉粥样硬化独立相关(OR=3.5)。
- 肝脏FDG摄取升高与冠状动脉高危斑块负荷增加相关。
核心结论
- 银屑病中亚临床肝病(肝脂肪变或肝炎)与亚临床动脉粥样硬化相关,提示其下游心血管效应。
研究设计与样本
- 两项观察性研究:欧洲队列纳入76例银屑病患者和76例对照;美国队列纳入162例接受PET和冠状动脉CTA的银屑病患者。
主要发现
- 欧洲队列中银屑病组非酒精性脂肪性肝病患病率61%高于对照45%(P=0.04)。
- 合并脂肪肝的银屑病患者亚临床动脉粥样硬化患病率61%,高于无脂肪肝银屑病患者23%(P=0.006)及合并脂肪肝对照32%(P<0.05)。
- 美国队列中肝脏FDG摄取高者非钙化、纤维脂肪及脂质丰富坏死核心冠状动脉负荷均更高(均P<0.001)。
关键数值与推荐
- 欧洲队列超声肝肾指数是银屑病亚临床动脉粥样硬化的决定因素(OR=3.5;P=0.01)。
- 美国队列肝脏FDG摄取与非钙化(β=0.28;P<0.001)、纤维脂肪(β=0.49;P<0.001)、脂质丰富坏死核心(β=0.28;P=0.003)负荷相关。
临床怎么用
- 对银屑病患者应评估肝脂肪变及肝脏炎症,并据此识别亚临床动脉粥样硬化高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is associated with a higher risk of liver diseases. We investigated the impact of hepatic steatosis (European cohort) and hepatic inflammation (United States cohort) on subclinical atherosclerosis. In the European cohort (n = 76 psoriasis participants and 76 controls), nonalcoholic fatty liver disease, assessed by the sonographic hepatorenal index, was more prevalent in psoriasis than in controls (61% vs. 45%; P = 0.04). Participants with psoriasis with nonalcoholic fatty liver disease had a higher prevalence of subclinical atherosclerosis (ultrasonographic presence of plaque in femoral or carotid arteries) than participants with psoriasis without nonalcoholic fatty liver disease (61% vs. 23%; P = 0.006) and controls with nonalcoholic fatty liver disease (61% vs. 32%; P < 0.05). Sonographic hepatorenal index was a determinant of subclinical atherosclerosis in psoriasis (OR = 3.5; P = 0.01). In the United States cohort (n = 162 participants with psoriasis who underwent positron emission tomography and coronary computed tomography angiography), those with high hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake had higher noncalcified (1.3 [0.49 mm2] vs. 1.0 [0.40 mm2]), fibrofatty (0.23 [0.15 mm2] vs. 0.11 [0.087 mm2]), and lipid-rich necrotic core (4.3 [2.3 mm2] vs. 3.0 [1.7 mm2]) coronary burden (all P < 0.001). Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated with noncalcified (β = 0.28; P < 0.001), fibrofatty (β = 0.49; P < 0.001), and lipid-rich necrotic core (β = 0.28; P = 0.003) burden. These results show the downstream cardiovascular effects of subclinical liver disease in psoriasis.
引用
- Gonzalez-Cantero A, Teklu M, Sorokin AV, et al. Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. J Invest Dermatol. 2021. PMID: 34293354. doi:10.1016/j.jid.2021.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。